financetom
Business
financetom
/
Business
/
Why Agile Therapeutics (AGRX) Stock Is Down 60%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Agile Therapeutics (AGRX) Stock Is Down 60%
Mar 26, 2024 9:33 AM

Agile Therapeutics Inc ( AGRX ) shares are trading lower by 61% to $0.24 during Tuesday’s session after the company announced the suspension of its trading on the Nasdaq effective Tuesday. The company received a final delisting notice from Nasdaq due to its failure to meet the minimum stockholders’ equity requirement. 

As a result, trading of its common stock on Nasdaq was suspended effective March 26. However, the company’s shares will still be publicly traded on the over-the-counter market operated by the OTC Markets Group Inc. under the symbol AGRX. 

Agile Therapeutics ( AGRX ) added and emphasized that this transition will not impact its business operations and reaffirms its commitment to executing its business plan and exploring strategic opportunities to enhance Twirla growth and shareholder value.

See Also: Is Donald Trump’s Truth Social’s Public Debut Worth The Hype? Expert Urges Caution

According to data from Benzinga Pro, AGRX has a 52-week high of $12.25 and a 52-week low of $0.20.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ValueAct reiterates backing for Disney amid boardroom fight with Trian
ValueAct reiterates backing for Disney amid boardroom fight with Trian
Mar 7, 2024
March 7 (Reuters) - Activist hedge fund ValueAct Capital reiterated its backing for Walt Disney ( DIS ) on Thursday amid a board challenge from billionaire Nelson Peltz's Trian Fund Management. As legacy technologies transition to digital platforms, we believe Disney ( DIS ) can lead the media industry forward, ValueAct Co-CEO Mason Morfit said in a statement. Disney (...
Dave Insider Sold Shares Worth $384,240, According to a Recent SEC Filing
Dave Insider Sold Shares Worth $384,240, According to a Recent SEC Filing
Mar 7, 2024
05:17 PM EST, 03/07/2024 (MT Newswires) -- Dan Preston, Director, on March 05, 2024, sold 12,000 shares in Dave ( DAVE ) for $384,240. Following the Form 4 filing with the SEC, Preston has control over a total of 33,039 shares of the company, with 33,039 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1841408/000109690624000355/xslF345X03/form4.xml Price: 36.99, Change: -0.11, Percent Change: -0.3 ...
Acv Auctions Insider Sold Shares Worth $936,000, According to a Recent SEC Filing
Acv Auctions Insider Sold Shares Worth $936,000, According to a Recent SEC Filing
Mar 7, 2024
05:17 PM EST, 03/07/2024 (MT Newswires) -- William Zerella, Chief Financial Officer, on March 05, 2024, sold 50,000 shares in Acv Auctions ( ACVA ) for $936,000. Following the Form 4 filing with the SEC, Zerella has control over a total of 323,286 shares of the company, with 323,286 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1637873/000095017024028146/xslF345X03/ownership.xml ...
Ero Copper Q4 Adjusted Net Income, Revenue Decline
Ero Copper Q4 Adjusted Net Income, Revenue Decline
Mar 7, 2024
05:18 PM EST, 03/07/2024 (MT Newswires) -- Ero Copper ( ERO ) reported Q4 adjusted net income Thursday of $0.21 per diluted share, down from $0.24 a year earlier. Analysts polled by Capital IQ expected $0.23. Revenue for the quarter ended Dec. 31 was $116.4 million, down from $116.7 million a year earlier. Analysts surveyed by Capital IQ expected $118.8...
Copyright 2023-2026 - www.financetom.com All Rights Reserved